Healthcare Industry News: Zotarolimus
News Release - May 18, 2007
Medtronic Announces Schedule of Activities at EuroPCR
Late-Breaking Trial Presentations Include Nine-Month Results for Endeavor RESOLUTE and Long-Term Data from Endeavor I and Endeavor II Clinical TrialsMINNEAPOLIS--(HSMN NewsFeed)--Medtronic, Inc. (NYSE:MDT ) today announced its schedule of major activities for the EuroPCR meeting, which begins May 22 at the Centre Convencions Internacional Barcelona (CCIB) in Barcelona, Spain. Highlighting the activities are two presentations at the late-breaking clinical trials session on the first day. During that session, Medtronic will present key nine-month results for Endeavor Resolute, its next-generation drug-eluting stent, as well as long-term data from the ENDEAVOR I and ENDEAVOR II clinical trials on the Endeavor(TM) drug-eluting stent.
Other activities include a satellite symposium on DES safety, plus several educational sessions on topics such as Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention, Endoluminal Treatments, Chronic Total Occlusions (CTO) and Percutaneous Valve Intervention. The schedule of major activities includes the following:
Tuesday, May 22
- Late Breaking Trials - Clinical Trial Update: 18:05 - 18:11 p.m. CEST, Room 1, CCIB. Dr. Ian Meredith, Monash Medical Centre, Melbourne, Australia, will present nine-month results from the Medtronic RESOLUTE clinical trial. Endeavor Resolute is Medtronic's next-generation drug-eluting stent featuring a proprietary new polymer, BioLinx. Medtronic will issue a news release on this data at the time of the presentation.
- Late Breaking Trials - Clinical Trial Update: 18:29 - 18:35 p.m. CEST, Room 1, CCIB. Dr. Andreas Zeiher, J.W. Goethe-University of Frankfurt, Germany, will present long-term safety and efficacy data on the Endeavor drug-eluting stent from the Endeavor I and Endeavor II clinical trials. The presentation will include 4-year data from Endeavor I and three-year data from Endeavor II. Medtronic will issue a news release on this data at the time of the presentation.
- Focus Session - 15 - 17:30 p.m. CEST, Room 9, CCIB. "Techniques for Optimising Outcomes of Coronary Chronic Total Occlusions." This physician symposium, chaired by Dr. Eric Eeckhout, Lasaunne, Switzerland, will review assessment of CTOs, selection of appropriate materials, overcoming difficulties, and review recorded live cases. Panelists include: M. Mason, U.K.; J. Koolen, Netherlands; S.T. Lim, Singapore; C. van Mieghem, Netherlands.
Wednesday, May 23
Satellite Symposium: 12 - 13:30 p.m. CEST, Room 1, CCIB. "DES - Current Questions, Future Perspectives." This physician symposium, chaired by Dr. Philip Urban, Geneva, Switzerland, will provide an update on long-term safety and efficacy data from the Endeavor clinical trial program, as well as information on topics such as: the new ARC definitions of stent thrombosis, insights on malapposition, the debate on proper duration of dual antiplatelet therapy, and DES safety in the future. Faculty: Jean Fajadet, Toulouse, France; Peter Fitzgerald, Stanford, California; Stephen Windecker, Bern, Switzerland; Sigmund Silber, Munich, Germany; Mitch Krucoff, Durham, North Carolina; Martin Rothman, London, U.K.
Thursday, May 24
Focus Session - 9 - 11:30 a.m. CEST, Room 7, CCIB. "Techniques for Optimising Outcomes of Acute Myocardial Infarction Interventions." This physician symposium, chaired by Dr. Bernard Chevalier, Saint-Denis, France, will discuss integration of primary percutaneous intervention in the management of patients with AMI, define specific role of dedicated technique in AMI, and review recorded live cases. Panelists include: Dr. P. Kala, Czech Republic; F. Kiemeneij, Netherlands; E Garcia, Spain; J. Bartunek; Czech Republic; E. Teiger, France.
About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.
Caution: The Endeavor Drug-Eluting Coronary Stent is an investigational device with an investigational drug (Zotarolimus) and exclusively for clinical investigation in the United States.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 28, 2006. Actual results may differ materially from anticipated results.
Source: Medtronic
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
Related News Items
Medtronic appoints Thierry Piéton as Chief Financial OfficerMedtronic Achieves CE Mark Approval for BrainSense Adaptive Deep Brain Stimulation and Electrode Identifier, a Groundbreaking Advance In Personalized, Sensing-Enabled Care for People with Parkinson's Through Innovative Brain-Computer Interface Technology
Medtronic Receives FDA Clearance for New InPen(TM) App, Paving the Way for its Smart MDI System Launch with Simplera(TM) CGM
